Abstract
RNA sequencing (RNA-seq) provides a powerful complement to DNA sequencing for uncovering pathogenic defects affecting gene expression and splicing in individuals with genetically undiagnosed rare disorders. However, as large rare disease consortia adopt RNA-seq, challenges arise due to cohort heterogeneity, variability in tissues and sample sizes, and differences in interpretation practices.
Here, we present a harmonized analytical and interpretation framework developed by the pan-European Solve-RD consortium to address these challenges. We analyzed 521 RNA-seq samples from whole blood, fibroblasts, muscle and peripheral blood mononuclear cells collected across more than 30 clinics and five European Reference Networks. Aberrant expression and splicing events were identified using OUTRIDER and FRASER 2.0 and analysed through a standardized four-level scoring framework that encompassed RNA-seq outlier reliability, phenotype relevance, variant mechanism, and segregation evidence, captured in structured reports for interpretation. Regular meetings, and collaborative “Solvathon” workshops were used to evaluate variant pathogenicity.
This effort resulted in molecular diagnoses for 19 families out of 248 (7.7%) for whom DNA analyses had been inconclusive. Furthermore, three cases diagnosed using DNA analyses were confirmed, and 49 candidate events and five novel candidate disease genes were identified in the remaining families. Our results demonstrate the feasibility and impact of large-scale, standardized RNA-seq analysis in a transnational research setting. This framework provides a model for other international initiatives such as the Undiagnosed Diseases Network and ERDERA, paving the way for broader clinical implementation of transcriptome-based rare disease diagnostics.
Competing Interest Statement
V.A.Y., F.B., and C.M., are founders, shareholders and managing directors of OmicsDiscoveries. The other authors declare no competing interests.
Clinical Trial
NCT03491280
Funding Statement
The SolveRD project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 779257. SolveRD research is supported (not financially) by ERN ITHACA (project ID no. 101085231), ERN RND (project ID no. 101155994), ERN EURO NMD (project ID no. 101156434), ERN EpiCARE (project ID 101156811), and ERN RITA (project ID 101155878). All ERNs are cofunded by the European Union within the framework of the Third Health Programme. ERDERA has received funding from the European Union Horizon Europe research and innovation programme under grant agreement 101156595. Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or any other granting authority, who cannot be held responsible for them. VAY, RL, CM and JG were supported by the Deutsche Forschungsgemeinschaft (German Research Foundation) via the project NFDI 1/1 GHGA German Human Genome Phenome Archive(441914366). The TUM IT infrastructure was cofunded via the Deutsche Forschungsgemeinschaft (German Research Foundation, project ID 461264291). BEA was supported by the predoctoral program Joan Oro of the Secretary of Universities and Research of the Department of Research and Universities of the Government of Catalonia with codes 2024 FI1 00075 and 2025 FI2 00075, cofinanced by the European Union. HM was supported by the Wellcome Trust grant 220906/Z/20/Z and UCL Global Engagement Fund scheme (2022/23 GEF project). HL receives support from the Canadian Institutes of Health Research (CIHR) for Foundation Grant FDN167281 (Precision Health for Neuromuscular Diseases), Transnational Team Grant ERT 174211 (ProDGNE) and Network Grant OR2 189333 (NMD4C), from the Canada Foundation for Innovation (CFI JELF 38412), the Canada Research Chairs program (Canada Research Chair in Neuromuscular Genomics and Health, 950 232279), the European Commission (101080249) and the Canada Research Coordinating Committee New Frontiers in Research Fund (NFRFG 2022 00033) for SIMPATHIC, and from the Government of Canada First Research Excellence Fund (CFREF) for the Brain-Heart Interconnectome (CFREF 2022 00007). KP is a recipient of a Canadian Institutes of Health Research (CIHR) postdoctoral fellowship award under award no: MFE 491707. JP was supported by the Else Kroener Fresenius Stiftung Clinician Scientist program precise.net and by the intramural TUFF program (3049 0 0). AP has received funding from the Secretariat for Universities and Research of the Ministry of Business and Knowledge of the Government of Catalonia (2021SGR00899), and the Instituto de Salud Carlos III (ISCIII) (FIS PI23/00835) Fondo Europeo de Desarrollo Regional (FEDER), Union Europea, una manera de hacer Europa. ASC was supported by the grants FPU20/06692 and EST23/00463 from Ministerio de Universidades, Spain. AH was supported by a ZonMW (The Netherlands Organization for Health Research and Development) Vici grant (No. 09150182310053). KL receives support from the German Research Foundation (DFG, LO1555/10 1). DNdB was supported by Instituto de Salud Carlos III (Grant CP22/00141).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of University Hospital of Tuebingen gave ethical approval for this work (ClinicalTrials.gov ID: NCT03491280, https://clinicaltrials.gov/study/NCT03491280). Informed consent for data sharing, including indirect identifiers within Europe for research, was obtained from all recruited individuals. All data submitters confirmed the code of conduct of RD-connect GPAP. This study adheres to the principles set out in the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw data will be available at the European Genome-Phenome Archive (https://ega-archive.org/datasets/) under the Solve-RD study EGAS00001003851, and can be accessed following approval from the Solve-RD Data Access Committee.
